Essential Partners’s Zenas BioPharma ZBIO Stock Holding History

Essential Partners’s Portfolio ZBIO Stock Details ZBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$54	Hold	2	–	–	﹤0.01%	2762
2026 Q2	$51	Hold	2	–	–	﹤0.01%	2791
2026 Q1	$39	Sell	2 -1	-33%	-$22	﹤0.01%	2797
2025 Q4	$109	Buy	3 +1	+50%	+$33	﹤0.01%	2539
2025 Q3	$44	Hold	2	–	–	﹤0.01%	2581
2025 Q2	$19	Buy	+2	New	+$19	﹤0.01%	2227

Other funds holding ZBIO

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

IFS Advisors Overland Park, Kansas $332M AUM 8.56% 1-Year Est. Return

FFO

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Essential Partners's ZBIO Position: Q3 2026 in Review

Essential Partners held its Zenas BioPharma (ZBIO) position steady in Q3 2026 at 2 shares worth $54. The position accounts for ﹤0.01% of the portfolio, ranked #2762.

Essential Partners first reported a position in ZBIO in Q2 2025 and has held it in 6 quarters since. The position peaked at $109 in Q4 2025. 6 funds tracked by Wall St. Rank hold ZBIO as of Q3 2026.

Essential Partners held 2 shares of Zenas BioPharma worth $54 as of Q3 2026.
Essential Partners left its Zenas BioPharma share count unchanged in Q3 2026.
Zenas BioPharma made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #2762 holding.
Essential Partners first reported a position in Zenas BioPharma in Q2 2025 and has held it in 6 quarters since.
Essential Partners's Zenas BioPharma position peaked at $109 in Q4 2025.
6 funds tracked by Wall St. Rank held Zenas BioPharma as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.